

Anand Yogesh Mehta, M.D.
Pacific Research Partners, LLC
901 Clay Street
Oakland, CA 94607

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 939-6696
Fax (208) 575-3169
Email: clinicaltrials@alliancesites.com

AFFILIATIONS:

Collaborative Neuroscience Network, LLC.
12772 Valley View Street, Suite 3
Garden Grove, CA 92845

Collaborative Neuroscience Network, LLC.
2600 Redondo Avenue, Suites 415 & 500
Long Beach, CA 90806

Collaborative Neuroscience Network, LLC.
19401 S. Vermont Avenue, Suite F-100
Torrance, CA 90502

Bay Valley Medical Group
University Healthcare Alliance
Hayward, CA

University of California – San Francisco
School of Medicine
San Francisco, CA

EDUCATION:

2004-2007 Board certified Endocrinologist
 Post-graduate Medical Training: Diabetes, Endocrinology, and Metabolism
 Fellowship
 Investigated the role of AMP Kinase in the modulation of growth and fat content
 in *C. elegans*
 University of California, San Francisco, School of Medicine

EDUCATION (continued):

- 1996-2001 Doctor of Medicine
 Regents Scholar, Howard Hughes Medical Institute Fellow
 University of California, San Francisco, School of Medicine
- 1992-1996 Bachelor of Arts, Molecular and Cell Biology
 Phi Beta Kappa, UC Berkeley Alumni Scholarship
 University of California, Berkeley

INTERNSHIPS AND RESIDENCIES:

- 2001-2004 Internal Medicine Internship and Residency Training
 Managed Acromegaly clinical research program to evaluate impact of novel
 therapeutics
 New York University, New York, School of Medicine

LICENSURE:

California Medical License A88443
DEA License BM9680047

CERTIFICATION:

Internal Medicine, 2004
Endocrinology Diabetes and Metabolism, 2007
Fellow of the American College of Physicians, Internal Medicine and Endocrinology

PROFESSIONAL EXPERIENCE:

Principal Investigator, Jan 2015-present
Pacific Research Partners, Oakland, CA

Sub-Investigator, March, 2014-present
Pacific Research Partners, Oakland, CA

Endocrinologist/Internist, 2012-present
Bay Valley Medical Group, Stanford University Healthcare Alliance, Hayward, CA

Assistant Clinical Professor of Medicine/Endocrinology, San Francisco General Hospital,
2007-present
University of California - San Francisco, School of Medicine, San Francisco, CA

Vice President, Healthcare Investment Banking Group, 2008-2012
Lazard Freres and Co., San Francisco, CA

PROFESSIONAL EXPERIENCE (continued):

Principal Investigator, Novel HDL Therapeutics, Novel Neurodegenerative Therapies, Pancreatic Beta Cell Modulators for Type 2 Diabetes, July 2007 – June 2008
KineMed, Inc, Emeryville, CA

INVESTIGATOR EXPERIENCE:

Phase I • Addiction • Binge Eating Disorder • Bipolar Disorder • Depression • Diabetes
Diabetic Peripheral Neuropathy • Fibromyalgia • Migraine • Schizophrenia and Schizoaffective
Disorder • Smoking Cessation • Tardive Dyskinesia • Vaccines

INVESTIGATOR INTEREST:

Alopecia Areata • Antivirals • Autoimmune Hemolytic Anemia • Autoimmune Hepatitis
Chronic Constipation • Chronic Fatigue • Chronic Pain • Cold Sores • Crohn's
Dermatology • Diabetes and Diabetic Related Diseases • Endocrinology • GERD
Graves' Disease • Growth Hormone Deficiency (adults only) • Hematology • Hepatitis B/ C
High Cholesterol • HIV • Hypertension • Hypotension Hyperlipidemia • Hyperphosphatemia
Idiopathic Thrombocytopenic Purpura • Infectious Diseases • Insomnia • Irritable Bowel
Men's and Women's Health - menopause, sexual dysfunction, hot flashes, hypogonadism, other
Obesity • Opioid Induced Constipation • Osteoarthritis • Pancreatitis • Pancreatic Insufficiency
Pemphigus/Pemphigoid • Psoriasis • Respiratory (COPD, Allergy, Asthma)
Thyroid (Hyperthyroidism, Hypothyroidism)

INVESTIGATOR EXPERIENCE:

Phase I

A randomized, placebo-controlled, double blind, single ascending and multiple ascending dose study to assess the safety, pharmacokinetics and pharmacodynamics of XXX in healthy volunteers and sickle cell disease patients (a first-in-human (FIH), Phase 1 study) and Open Label Extension

Depression

A Phase III, Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of XXX in the Treatment of Adults with Severe Postpartum Depression

Diabetes

A Phase III, Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of XXX in Type 1 Diabetes Mellitus Patients

A Phase II, Multicenter, Randomized, Double blind, Placebo- controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of Twelve Once-Weekly Subcutaneous Doses of XXX in Subjects with Type 2 Diabetes (T2DM) Not Well Controlled by Metformin

INVESTIGATOR EXPERIENCE (continued):

A Phase III, 26-week randomized, open-label, active-controlled, 2-treatment arm, parallel-group multi-center study, comparing the efficacy and safety of XXX vs. XXX in ethnically/racially diverse patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic agents with a 26-week extension period

A Phase III, Randomized, Double Blind, Parallel Arm Study of the Efficacy and Safety of Investigational XXX Doses When Added to Metformin in Patients with Type 2 Diabetes Mellitus

A Phase III, Randomized, Multi-center, Double-Blind, Parallel-Group Clinical Study Comparing the Efficacy and Safety of XXX Produced by Two Manufacturing Processes in Type 1 Diabetes Mellitus Patients

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Add-on Study of XXX in Adults with Uncontrolled Type 2 Diabetes on Metformin Therapy

A Phase III, Randomised, Double blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of XXX as Adjunctive to Insulin Therapy Over 26 Weeks in Patients with Type 1 Diabetes Mellitus

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXX in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of XXX Following 12 weeks Administration in Subjects with Type 2 Diabetes Mellitus on a Stable Dose of Metformin

A Phase II, Randomized, Double-blind, Parallel Group, Multicenter, Placebo-controlled, Dose-ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of XXX Delayed-Release in Subjects with Type 2 Diabetes Mellitus

A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of XXX, when added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

A Phase IIIb, Randomized, Open-Label, Parallel study Comparing Human Regular Insulin U-500 Delivered by Continuous Subcutaneous Insulin Infusion (XXX Insulin Management System for use with Regular Human Insulin U-500) to Delivery by Multiple Daily Injections in High-Dose Insulin-Requiring Patients with Type 2 Diabetes Mellitus who have Inadequate Glycemic Control on Existing High Dose Insulins (with or without other insulins/antihyperglycemic agents)

INVESTIGATOR EXPERIENCE (*continued*):

A Phase III Randomized, Open-Label, 2-Arm Parallel-Group, Multicenter, 30-Week Study Assessing the Safety and Efficacy of XXX Versus XXX in Older Patients With Type 2 Diabetes Inadequately Controlled on Antidiabetic Regimens Either Including No Insulin, or With Basal Insulin as Their Only Insulin

Migraine

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral XXX for the Prophylaxis of Migraine in Participants with Episodic Migraine Who Have Previously Failed 2 to 4 Classes of Oral Prophylactic Treatments

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of XXX Nasal Powder in the Acute Treatment of Migraine

A Phase III, Multicenter, Randomized, Open-label Study to Evaluate the Longterm Safety and Tolerability of Oral XXX for the Prevention of Migraine in Patients with Episodic Migraine

A Phase III, Randomized, Double blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of XXX in Migraine Prevention

A Multicenter, Open Label, Long-Term Safety Study of XXX in Patients with Acute Migraines

A Phase III, Double-Blind, Randomized, Placebo Controlled, Safety, Efficacy, Trial of XXX for the Acute Treatment of Migraine

A Phase III, Open-label, Long-term, Safety Study of XXX (100 mg and 200 mg) in the Acute Treatment Of MigRaine

A Phase III, Study of Three Doses of XXX (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

Pain

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of XXX in Subjects with Diabetic Peripheral Neuropathic Pain

A Randomized Withdrawal, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of XXX ® Tablet, XXX, in Patients with Moderate-to-Severe Chronic Low Back Pain

INVESTIGATOR EXPERIENCE (continued):

Vaccines

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter study of 2 Dose Levels of XXX Administered as Immunotherapy and 1 Dose Level of XXX Administered in Combination with XXX for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Other Indications

A Phase II, Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral XXX , a Pyruvate Kinase Activator in Patients With Sickle Cell Disease

A randomized, double-blind, placebo-controlled study to investigate the efficacy of XXX in subjects affected by motion sickness during travel

SUB-INVESTIGATOR EXPERIENCE:

Phase I

A Phase Ib, Pivotal, Multiple-Dose, Pharmacokinetic Bioequivalence Trial Comparing Generic to Reference XXX Extended-Release Injectable Suspension (156 mg/1.0 mL) in Patients with Schizophrenia or Schizoaffective Disorder

A Phase I, Randomized, Crossover, Open-Label, Multiple Dose, Pivotal Pharmacokinetic Bioequivalence Study Comparing XXX Extended-Release IM 156 mg/1 mL (100 mg eq) with XXX in Subjects with Schizophrenia or Schizoaffective Disorder

A Phase I, XXX Sub-study 002: Study of XXX and Android App Performance and Usability.

A Phase I, “RW2 Confirmatory Study” of the XXX system. The system is designed to enable mental health patients to measure and monitor their medication adherence as well as other information such as mood, rest, and activity.

A Phase I Randomized, Open-Label, Parallel Design, Multiple-Dose, Comparative Bioequivalence Study of XXX Extended-Release Injectable Suspension (156 mg/1.0 mL) Versus XXX Extended-Release Injectable Suspension (156 mg/1.0 mL) in Schizophrenia Patients Already Stabilized on XXX

A Phase I, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXX Following Administration to the Deltoid or Gluteal Muscle in Adults with Schizophrenia or Schizoaffective Disorder

SUB-INVESTIGATOR EXPERIENCE (*continued*):

A Phase I, Reliability and validity of an online neurocognitive test battery, the XXX Test, in normal healthy adults

A Phase I Study of XXX and XXX Co-administered with XXX in Adults with Schizophrenia

Phase II-IV

Addiction

A Phase III, Open-Label, Depot XXX Treatment Extension Study in Subjects With Opioid Use Disorder

A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study with Follow-up Evaluating the Safety and Efficacy of XXX for Smoking Cessation in Healthy Adolescent Smokers

A Phase III, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of XXX in the Treatment of Adults with Binge Eating Disorder

Bipolar Disorders

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of XXX Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression)

A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Fixed-dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of XXX in Patients with Bipolar I Depression

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Once a Day, XXX Tablet for Sublingual Administration (XXX Tablet) 0.1 mg and 0.4 mg as an adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar I Disorder in Adult Subjects Who Are on Lithium or Valproate

Depression

A Double-Blind, Placebo-Controlled, Phase II Trial to Test Efficacy and Safety of XXX as Adjunct to Current Antidepressant Therapy in Patients with Major Depressive Disorder (MDD) with an Inadequate Response to Current Antidepressants

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of XXX as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder

SUB-INVESTIGATOR EXPERIENCE (*continued*):

A Double-Blind, Placebo-Controlled, Fixed-Dose Study of XXX in Patients with Major Depressive Disorder

A Study of XXX Plus XXX in Treatment-Resistant Depression (TRD)

A Phase II/III, Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of XXX Administered Orally to Subjects with Treatment Resistant Major Depressive Disorder

A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive XXX in Major Depressive Disorder

An Open-Label, Single-Arm, Multicenter, Prospective, Phase IV, Interventional, Flexible Dose Study to Evaluate the Effectiveness of XXX on Goal Achievement After a Change in Antidepressant Medication for the Treatment of Subjects With Major Depressive Disorder - Goal Achievement After a Change to XXX in Adults With Major Depressive Disorder

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of XXX in the Treatment of Subjects with Severe Depression despite Antidepressant Treatment

A Phase III, Open-label Long-term Extension Safety Study of Intranasal XXX in Treatment-resistant Depression

A Phase III, 8-Week Prospective Randomized, Controlled, Single-Blind Trial of the XXX vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults with Major Depressive Disorder

A Phase III, Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal XXX Plus an Oral Antidepressant in Adult Subjects with Treatment-resistant Depression

A Phase III Multicenter Study of the Long-term Safety and Tolerability of XXX for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy

A Phase III Efficacy and Safety Study of XXX for the Adjunctive Treatment of Major Depressive Disorder

A Double-Blind, Placebo-Controlled, Randomized Add-On Study of XXX for Patients With Major Depressive Disorder (MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy

SUB-INVESTIGATOR EXPERIENCE (*continued*):

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of XXX in the Adjunctive Treatment of Subjects with Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

Fibromyalgia

An Open-label Extension Study of XXX for 52 weeks in Pain Associated with Fibromyalgia

A randomized, double-blind, double-dummy, placebo- and active-controlled, multi-center study of XXX in subjects with pain associated with fibromyalgia

Migraine

A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy, Tolerability, and Safety Study of XXX in Episodic Migraine With or Without Aura

A Phase III, Open-label, Long-term, Safety Study of XXX (100 mg and 200 mg) in the Acute Treatment Of Migraine

A Phase III, Study of Three Doses of XXX (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of XXX in Patients with Episodic Migraine - the XXX 2 Study

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of XXX Administered Intravenously in Patients with Chronic Migraine

Schizophrenia

To create opportunities for the XXX Sponsor to interface with people with schizophrenia and to obtain their feedback on XXX prototypes

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Assess the Safety and Efficacy of XXX as Add-on Treatment for Cognitive Impairment in Subjects with Schizophrenia on Stable Doses of Antipsychotic Medication

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension XXX for Subcutaneous Use as Maintenance Treatment in Adult Patients with Schizophrenia

SUB-INVESTIGATOR EXPERIENCE (*continued*):

A Double-blind, Randomized, Active-controlled, Parallel-group Study of XXX 6-Month Formulation

A Phase IIb/III, Adaptive, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of XXX, a D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adults

Pilot study for Validation Test Plan XXX study

A Phase III, Open-Label, Multi-Center Trial to Assess the Safety and Effectiveness of XXX in Patients with Schizophrenia

A Phase IIb, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of XXX as Adjunctive Treatment in Patients with Cognitive Impairment Associated with Schizophrenia Treated with Antipsychotics

A Phase III, 52-Week, Open-Label, Extension Study of XXX for the Adjunctive Treatment of Schizophrenia

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive XXX for the Treatment of Schizophrenia

A Phase II, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of XXX, a Component of XXX, in Adults with Schizophrenia Treated with Olanzapine

A Phase III Study to Evaluate Weight Gain of XXX Compared to XXX in Adults with Schizophrenia

A Phase III, One Year, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXX as a Maintenance Treatment in Patients with Schizophrenia

XXX for Cannabis Use Disorder in Schizophrenia

A Phase III, Study to Evaluate Weight Gain of XXX Compared to XXX in Adults with Schizophrenia

An Open-Label, Long-Term Safety and Tolerability Study of XXX in the Treatment of Subjects With Schizophrenia

SUB-INVESTIGATOR EXPERIENCE (*continued*):

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of XXX (90-mg and 120 mg) as a Treatment in Subjects with Acute Schizophrenia Over 8 Weeks

A Phase II, Randomized, Double-blind Study to Evaluate Efficacy, Safety, and Tolerability of XXX in Subjects with Schizophrenia with Alcohol Use Disorder

A Phase III, Multicenter, Extension of Study XXX to Assess the Long-term Safety and Durability of Effect of XXX in Subjects with Stable Schizophrenia

A 12-Week, Randomized, Phase II, Double-blind, Parallel-group, Study of Two Dose Levels of XXX Compared to Placebo in the Adjunctive Treatment of Outpatients with Sub-Optimally Controlled Symptoms of Schizophrenia

A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase III Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist XXX or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

A Phase III Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of XXX an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy

Tardive Dyskinesia

A Phase III, Open-Label Rollover Study for Continuing XXX Administration for the Treatment of Tardive Dyskinesia

A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel, Fixed-dose Study to Assess the Efficacy, Safety, and Tolerability of XXX for the Treatment of Tardive Dyskinesia

A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered XXX in Subjects with Drug-Induced Tardive Dyskinesia

Other Indications

A Phase II/III Randomized, Double-blind, Placebo-controlled trial of XXX in Subjects with Obsessive Compulsive Disorder

A Phase III, 12-Week Open-Label Extension Study to Evaluate XXX Taken Daily at Bedtime in Patients with PTSD

SUB-INVESTIGATOR EXPERIENCE (*continued*):

A Phase III, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX Taken Daily at Bedtime in Patients with Military-Related PTSD

PUBLICATIONS:

Clarissa L. Waites, **Anand Y. Mehta**, Philip Tan, Gary Thomas, Robert H. Edwards, and David E. Krantz, An Acidic Motif Retains Vesicular Monoamine Transporter-2 on Large Dense-Core Vesicles, *Journal of Cell Biology*, March 19, 2001, Vol. 152(6):1159-1168.

Stephen K. Doberstein, Richard D. Fetter, **Anand Y. Mehta**, and Corey S. Goodman, Genetic Analysis of Myoblast Fusion: *blown fuse* in Required for Progression Beyond the Prefusion Complex, *Journal of Cell Biology*, March 1997, Vol. 136:1249-1261.

John Salmeron, Susan Barker, Francine Garland, **Anand Y. Mehta**, and B.J. Staskawicz, Tomato Plants Altered in Bacterial Disease Resistance Provide Evidence for a New Locus Controlling Pathogen Recognition, *The Plant Cell*, April 1994, Vol. 6:511-520.

PRESENTATIONS:

Transcriptional Regulation of Metabolic Networks, Keystone Symposia on Obesity and Diabetes, Keystone, CO: 2005

Andropause: Fact or Fiction, New York University, Resident Lecture Series: 2004

The Differential Localization of Vesicular Neurotransmitter Transporters in Neurons, Howard Hughes Medical Institute, Medical Student Conference, Chevy Chase, MD: 2000

AWARDS & HONORS:

Keystone Symposia on Obesity and Diabetes Travel Grant, Keystone, CO (2005)

Endocrine Fellows Foundation Research Grant (2004)

Howard Hughes Medical Institute, Medical Student Research Award for the Completion of Medical Studies (2000)

Howard Hughes Medical Institute, Research Training Fellowship for Medical Students (1999)

UCSF Regents Scholarship, renewed yearly (1996-2000)

Phi Beta Kappa National Honor Society (1995)

Golden Key National Honor Society (1995)

UC Berkeley Dean's Honor Roll (1992-1996)

UC Berkeley Alumni Scholarship (1992)